CAIP(603035)2025-04-18 09:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,337,611,956.58, representing a year-on-year increase of 26.31% compared to CNY 1,059,003,670.83 in the same period last year[2] - The net profit attributable to shareholders of the listed company decreased by 16.03% to CNY 87,655,798.48 from CNY 104,394,220.90 in the previous year[2] - The net profit after deducting non-recurring gains and losses fell by 36.68% to CNY 68,154,154.60, primarily due to a decline in investment income from joint ventures and associates[4] - The company reported a significant increase in contract assets by 44.14%, attributed to increased sales of molds[4] - Total operating revenue for Q1 2025 reached ¥1,337,611,956.58, an increase of 26.2% compared to ¥1,059,003,670.83 in Q1 2024[15] - Net profit for Q1 2025 was ¥84,588,653.27, a decrease of 17.6% from ¥102,593,308.70 in Q1 2024[16] - The company reported a gross profit margin of approximately 2.6% for Q1 2025, down from the previous year's margin[15] - The company’s net profit for Q1 2025 is not explicitly stated in the provided documents, indicating a need for further details on profitability metrics[25] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -18,769,221.96, a decrease of 164.80% compared to CNY 28,962,795.80 in the previous year[2] - The total cash flow from operating activities for Q1 2025 is yet to be detailed in the provided documents[18] - In Q1 2025, the cash inflow from operating activities was CNY 781,498,320.61, a decrease of 5.57% compared to CNY 827,578,388.39 in Q1 2024[19] - The total cash outflow from investing activities was CNY 89,217,325.27, down from CNY 113,956,775.78 in Q1 2024, resulting in a net cash flow from investing activities of CNY -76,207,703.84[20] - Cash inflow from financing activities increased significantly to CNY 219,059,297.56, compared to CNY 41,633,873.70 in Q1 2024, leading to a net cash flow from financing activities of CNY 47,066,939.33[20] - The company's cash and cash equivalents decreased to RMB 424,086,786.39 from RMB 528,930,405.22 year-over-year, reflecting a decline of approximately 19.7%[10] - The company's cash and cash equivalents at the end of Q1 2025 were CNY 316,371,623.19, down from CNY 277,127,635.15 in Q1 2024[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 10,784,220,228.80, reflecting a slight increase of 1.36% from CNY 10,639,440,406.35 at the end of the previous year[2] - The company's total liabilities increased to ¥5,430,419,458.78 in Q1 2025, compared to ¥5,325,149,824.97 in Q1 2024, marking a rise of 2%[12] - The total equity attributable to shareholders reached ¥5,223,093,219.49, up from ¥5,180,515,885.64 in the previous year, indicating a growth of 0.8%[13] - The total assets as of March 31, 2025, were CNY 5,627,205,318.97, an increase from CNY 5,482,537,962.87 at the end of 2024[24] - Current liabilities rose to CNY 1,685,162,478.99, up from CNY 1,576,892,443.79 at the end of 2024, primarily due to an increase in short-term borrowings[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,646[6] - The company has repurchased a total of 10,312,153 shares, representing 2.7135% of the total share capital, with a total expenditure of RMB 149,970,565.00[8] - The highest repurchase price was RMB 14.90 per share, while the lowest was RMB 13.80 per share[8] - The company is committed to timely information disclosure regarding the ongoing share repurchase program[9] Research and Development - Research and development expenses for Q1 2025 were ¥55,176,885.45, compared to ¥52,115,070.54 in Q1 2024, reflecting an increase of 5.9%[15] - Research and development expenses for Q1 2025 were ¥2,244,346.84, down from ¥3,193,703.60 in Q1 2024, reflecting a decrease of approximately 29.7%[26]